

Date: June 28, 2025

BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 001

BSE Scrip Code: 506943 Stock Symbol: JBCHEPHARM

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("Listing Regulations")

Sub: Outcome of board meeting in compliance with Regulation 30 of the Listing Regulations

Dear Sir / Madam,

In compliance with Regulation 30 read with Paragraph (A)(7) of Part A of Schedule III of the Listing Regulations, we write to inform you that the Board of Directors ("Board") of J.B. Chemicals & Pharmaceuticals Limited ("Company"), at its meeting held today i.e., June 28, 2025 has, inter alia, based on the recommendation of the Nomination and Remuneration Committee of the Company, approved the re-appointment Mr. Nikhil Ashokkumar Chopra (DIN: 07220097) as the Chief Executive Officer and Whole-time Director of the Company for a period 5 years from October 5, 2025 to October 4, 2030 subject to approval by members in the ensuing annual general meeting of the Company.

The requisite disclosures in terms of Regulation 30 of the Listing Regulations read with Clause A(7) of Annexure 18 of the Securities and Exchange Board of India ("SEBI") master circular dated November 11, 2024 bearing reference no. SEBI/HO/CFD/PoD2/CIR/P/0155 ("Master Circular") in this regard are enclosed hereto as "Annexure A".

We request you to kindly take the above disclosure on record.

Thanking you, Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Limited

Sandeep Phadnis Vice President – Secretarial & Company Secretary





Annexure A

Disclosure under Regulation 30 of the Listing Regulations read with A(7) of Annexure 18 of the Master Circular

Sr.	Particulars	Details
No.		
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment. Mr. Nikhil Ashokkumar Chopra current term as Chief Executive Officer and Whole-time Director of the Company ends with effect from close of business hours on October 4, 2025. Based on the recommendation of the Nomination and Remuneration Committee of the Company, the Board has approved the re-appointment Mr. Nikhil Ashokkumar Chopra (DIN: 07220097) as the Chief Executive Officer and Whole-time Director of the Company for a period of 5 years from October 5, 2025 to October 4, 2030 subject to approval by members in the ensuing annual general meeting of the Company.
2.	Date of appointment/ re-appointment /cessation (as applicable) & term of appointment/re-appointment	October 5, 2025
3.	Brief profile (in case of appointment)	As attached.
4.	Disclosure of relationships between directors (in case of appointment of a director	Mr. Nikhil Ashokkumar Chopra is not related inter-se to any other director of the Company.
5.	Information as required pursuant to BSE Limited circular dated 20 June 2018 bearing reference no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited circular dated 20 June 2018 bearing reference no. NSE/CML/2018/24	Mr. Nikhil Ashokkumar Chopra is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.



Brief Profile of Mr. Nikhil Chopra:

Mr. Nikhil Chopra is a seasoned business leader in the pharmaceutical industry, currently serving as the CEO & Whole Time Director at JB Pharma since October 5, 2020. In this role, he is responsible for transforming the company and shaping its vision for 2026. With more than two decades of experience, Mr. Nikhil Chopra has consistently demonstrated his ability to drive sustainable growth and create significant shareholder value. As a visionary leader, Mr. Nikhil Chopra excels in assembling talented teams to address challenges and turn them into opportunities. His leadership style is marked by a focus on innovation, quality treatment, and improving medicine accessibility. Mr. Nikhil Chopra has been instrumental in introducing groundbreaking ideas to enhance access to high-quality treatments, positioning JB Pharma as the fastest-growing company among the top 25 in the pharmaceutical industry, for two consecutive years!

Under his guidance, JB Pharma has achieved an outstanding growth rate of 16%, surpassing the industry average of 10% as per IQVIA MAT Dec'23 data. Mr. Nikhil Chopra strategic approach includes spearheading inorganic acquisitions and transforming them into successful businesses, enabling the company to venture into progressive therapies such as heart failure, probiotics, cardiac care and ophthalmology and create better accessibility. This aggressive strategy has elevated JB Pharma to one of the top 10 players in cardiology therapy in the Indian pharmaceutical market and the leader in the hypertension segment. As a result of his dynamic strategy and foresight, the company's revenue nearly doubled, reaching INR 3000+ crore in FY23, with 6 of its major brands ranking in the top 300 Indian pharmaceutical brands. JB is amongst the Top 5 largest manufacturers of lozenges, globally!

Mr. Nikhil Chopra is an advocate for sustainable business practices. Under his stewardship, JB Pharma released its second Sustainability Report, underscoring the commitment to embedding responsible practices across all operations and ensuring transparency in the company's progress toward its ESG (Environmental, Social, and Governance) objectives.

At JB, he has played an instrumental role in leadership development programmes and fostering cross-functional collaborations within the organization. Another impactful initiative was the enhancement of training programs for field force, emphasizing sales force automation and excellence by equipping the field force with cutting-edge technological tools, including digital promotion capabilities. Today JB Pharma boasts a strong India field force of 3000+ with therapy focused segmentation. Mr. Nikhil Chopra is also a catalyst for change in the industry, introducing the concept of 'Beyond The Pill' marketing. This involves implementing "phygital" initiatives to enhance patient awareness, education, diagnosis, and adherence. He has played a crucial role in talent development and fostering crossfunctional collaborations within the organization.



Prior to JB Pharma, Mr. Nikhil Chopra served as the CEO-India Business at a leading pharmaceutical company for an impressive 24 years. His dedication, strategic vision, and industry expertise have positioned him as a prominent figure in the pharmaceutical sector, leading JB Pharma towards a successful and transformative future.